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Endothelial dysfunction has been found to be linked to
and predictive of cardiovascular events. Whether endothelial
function of the renal vasculature is impaired in patients with
chronic glomerular disease and whether oxidative stress is of
importance in this setting has not yet been determined. In
this study, endothelial function of the renal vasculature was
investigated in 25 patients with chronic glomerular disease
and 50 control subjects matched for age and blood pressure.
Renal plasma flow (RPF) and glomerular filtration rate were
measured by constant infusion input clearance technique
at baseline and following infusions of the nitric oxide
synthase (NOS) inhibitor NG-monomethyl-L-arginine
(L-NMMA, 4.25 mg/kg), the substrate of NOS L-arginine
(100 mg/kg) and the antioxidant vitamin C (3 g co-infused
with L-arginine 100 mg/kg). At baseline, RPF was similar in the
two groups. The reduction in RPF in response to L-NMMA was
less pronounced in patients with chronic glomerular disease
compared to control subjects (4.6712 vs 9.879%;
P¼ 0.040), indicating reduced basal nitric oxide (NO) activity
in chronic glomerular disease. Co-infusion of the antioxidant
vitamin C on top of L-arginine induced a more pronounced
increase in RPF in patients with chronic glomerular disease
than in control subjects (21.7717 vs 10.9722%; P¼ 0.036).
Our findings suggest that basal NO activity of the renal
vasculature is reduced in patients with chronic glomerular
disease compared to age- and blood pressure-matched
control subjects. This might be in part related to increased
oxidative stress.
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Endothelial dysfunction has emerged as an important
pathogenetic and prognostic factor in the development and
progression of atherosclerotic vascular disease.1–3 Impairment
of endothelial function has also been demonstrated to play a
major role in glomerulosclerosis and tubulointerstitial
fibrosis in chronic kidney disease, at least in part being
mediated through reactive oxygen species (ROS).4–7 ROS
such as superoxide anion reduce the activity of the
endothelium-derived vasodilator nitric oxide (NO) by the
formation of peroxynitrite.4 Data from animal models also
suggest that endothelial dysfunction and ROS contribute to
glomerular damage in minimal-change glomerulopathy,
mesangioproliferative, membranous, and focal segmental
necrotizing glomerular disease.8–11 These experimental find-
ings in animals clearly link the presence of increased oxidative
stress and endothelial dysfunction to glomerular disease.
Whether such an association is also evident in humans has
not yet been adequately addressed.
Direct assessment of endothelial nitric oxide synthase
(NOS) activity or ROS in the kidney is highly invasive.
However, alternative methods to assess endothelium-depen-
dent, NO-mediated vasodilaton as a parameter of endothelial
integrity have recently been established and validated.12–14
With regards to the renal vasculature, endothelium-
dependent vasodilation can be measured by assessment of
the vasoconstrictive response to systemic administration of
the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA),
indicative of basal NO activity.13,14 Thus, a pronounced vaso-
constrictor response to L-NMMA, for example, an exagge-
rated decrease in renal plasma flow (RPF), reflects high basal
NO activity and vice versa. Administration of L-arginine, the
substrate of NOS, leads to an increase in RPF, that is, at least
in part dependent on endothelial cell integrity, particularly
when a dose of 100 mg/kg body weight is used.12,13 In
addition, the antioxidant vitamin C can safely be applied in
humans to examine the role of oxidative stress for alterations
of endothelial function of the renal vasculature.15,16
The aim of this study was to characterize endothelial
function of the renal vasculature in patients with chronic
glomerular disease by NOS inhibition and NOS stimulation,
and to determine the potential contribution of oxidative
stress to NO activity in these subjects using the antioxidant
potential of vitamin C.
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RESULTS
Study population
Baseline characteristics of the two study populations are
given in Table 1. With the exception of body weight, body
mass index, and serum creatinine, there were no significant
differences in baseline characteristics between the two groups.
Histological diagnosis of the underlying chronic glomerular
disease was obtained from kidney biopsies in all 25 patients:
mesangioproliferative glomerulonephritis (n¼ 5), immuno-
globulin A-glomerulonephritis (n¼ 4), thin base membrane
syndrome (n¼ 2), chronic glomerulonephritis (n¼ 7), mini-
mal change glomerulonephritis (n¼ 1), diabetic nephropathy
(n¼ 3), membranous glomerulonephritis (n¼ 1), and focal
segmental glomerulosclerosis (n¼ 2).
Systemic hemodynamic parameters
Effects of L-NMMA, L-arginine, and L-arginine plus vitamin
C on systemic hemodynamic parameters are shown
in Table 2. Administration of L-NMMA led to an increase
in mean arterial blood pressure and decrease in heart rate,
without any significant differences between the two groups.
L-arginine alone as well as in combination with vitamin C
caused similar decreases in mean arterial blood pressure and
an increase in heart rate in the two groups.
Renal hemodynamic parameters
At baseline, RPF was similar between patients with
glomerular disease and control subjects (Table 3). In control
subjects, L-NMMA clearly reduced RPF when compared to
baseline levels (Po0.001), whereas in patients there was only
a trend towards such a reduction in response to L-NMMA
(P¼ 0.052) (Table 3). Compared to controls, the decrease
in RPF in response to inhibition of NOS by L-NMMA
was blunted in patients (controls: 9.879.3% vs patients:
4.6712.0%; P¼ 0.040) (Table 3 and Figure 1), indicating
reduced basal NO activity in patients with glomerular
disease.
Infusion of L-arginine led to a significant increase in RPF
compared to the levels after L-NMMA in both groups
(controls: Po0.001; patients: Po0.01) (Table 3). The
magnitude of the increase in RPF in response to L-arginine
did not differ between the two groups (Figure 1).
Concomitant administration of vitamin C led to a further
increase in RPF in the two groups, compared to either
Table 1 | Clinical characteristics
Renal
patients (n=25)
Controls
(n=50) P-value
Age (years) 53711 4979 NS
Gender (male/female) 18/7 32/18 NS
Weight (kg) 95714 77717 o0.01
Height (cm) 17577 171710 NS
BMI (kg/m2) 3175 2675 0.01
Systolic blood pressure (mmHg) 131723 137716 NS
Diastolic blood pressure (mmHg) 79710 83712 NS
Urinary protein excretion (g/day) 3.071.9 — —
Serum creatinine (mg/dl) 1.370.6 0.970.2 o0.01
BMI, body mass index; NS, not significant.
All data are given as mean7s.d.
Table 2 | Systemic hemodynamics in response to infusion of
L-NMMA, L-arginine, and L-arginine plus vitamin C
Renal
patients
(n=25)
Controls
(n=50) P-value
MAP at rest (mmHg) 98714 101713 NS
MAP after L-NMMA (mmHg) 107716 109715 NS
MAP after L-arginine (mmHg) 98717 101713 NS
MAP after L-arginine plus vitamin C
(mmHg)
100716 102714 NS
HR at rest (b.p.m.) 63711 6478 NS
HR after L-NMMA (b.p.m.) 60711 5977 NS
HR after L-arginine (b.p.m.) 65712 6778 NS
HR after L-arginine plus vitamin C (bpm) 65712 6878 NS
HR, heart rate; L-NMMA, NG-monomethyl-L-arginine; MAP, mean arterial pressure; NS,
not significant.
All data are given as mean7s.d.
Table 3 | Renal hemodynamics after infusion of L-NMMA,
L-arginine, and L-arginine plus vitamin C
RPF (ml/min/1.73 m2)
Renal
patients
(n=25)
Controls
(n=50)
P-value
(patients vs
controls)
RPF at rest 4977189 4917108 NS
RPF after L-NMMA 4627151 439794** NS
RPF after L-arginine 5197174* 5047122** NS
RPF after L-arginine plus
vitamin C
5717188** 5527163** NS
D % RPF after L-NMMA 4.6712.0 9.879.3 0.040
D % RPF after L-arginine +6.4711.2 +3.4716.9 NS
D % RPF after L-arginine
plus vitamin C
+21.7716.8 +10.9722.4 0.036
L-NMMA, NG-monomethyl-L-arginine; NS, not significant; RPF, renal plasma flow.
D% indicates percent change in RPF from baseline, all data are given as mean7s.d.
*Po0.01, **Po0.001 vs RPF before intervention.
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Figure 1 | Changes of RPF following infusion of L-NMMA,
L-arginine alone, and L-arginine infused concomitantly with the
antioxidant vitamin C. Values are given in mean change from
baseline (%)7s.e.m. Values and changes of RPF are also given in
Table 3.
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baseline (both Po0.001) or to the level after L-arginine
infusion (both Po0.001) (Table 3). The magnitude of
the increase in RPF in response to vitamin C co-infused
with L-arginine was substantially higher in patients than in
control subjects (21.7716.8 vs 10.9722.4%; P¼ 0.036)
(Figure 1), indicating an increased potential of antioxidant
therapy to improve RPF in patients, that is, increased
oxidative stress in the renal vasculature of patients with
chronic glomerular disease.
Glomerular filtration rate (GFR) at baseline was higher in
patients compared to controls (114718 vs 102725 ml/min/
1.73 m2; P¼ 0.04). However, changes in glomerular fitration
rate in response to infusion of L-NMMA, L-arginine, and
L-arginine co-infused with vitamin C did not differ between
patients and control subjects (Figure 2).
Filtration fraction was similar in both groups at baseline
(controls: 23.772.7% vs patients: 22.575.4%). The change
in filtration fraction in response to L-NMMA infusion
was more marked in control subjects than in patients
(15.5711.1 vs 8.9713.1 %; Po0.05). Changes in filtration
fraction in response to L-arginine (5.1710.7 vs 0.5710.3 %;
P¼NS) and L-arginine plus vitamin C (3.4718.7 vs
9.3710.4%; P¼NS) did not differ between control
subjects and patients.
DISCUSSION
This is the first study to demonstrate that basal NO activity of
the renal vasculature is reduced in patients with chronic
glomerular disease as compared to an age- and blood
pressure-matched control group. Increased oxidative stress
in the renal vasculature of patients with chronic glomerular
disease appears to contribute to the reduction of basal NO
activity in these patients, as indicated by an exaggerated
increase in RPF in response to infusion of the antioxidant
vitamin C. Thus, our data provide clinical support for
experimental data, linking increased oxidative stress and
decreased NO activity with glomerular disease.
Infusions of L-arginine and L-NMMA have been widely
used to analyze endothelial function of the renal vascu-
lature.12–14,16,17 L-arginine is the substrate for NOS and
systemic infusion of L-arginine results in NO-dependent
vasodilation. L-NMMA is a competitive inhibitor of
endothelial NOS. Therefore, L-NMMA infusion allows
assessment of basal NO activity, that is, assessment of the
contribution of NO to the balance between vasodilator and
vasoconstrictor agents. Inhibition of endothelial NOS by
systemic infusion of L-NMMA results in a decrease of NO
activity with a consecutive increase in vascular tone. In
the renal vasculature, the effects of L-NMMA infusion on
vascular tone can be assessed by measuring the decrease in
RPF.12–14,17,18 In a state of high basal NO activity, blockade of
NOS by L-NMMA results in a distinct decrease of RPF,
whereas the fall in RPF in response to L-NMMA will be less
pronounced in a setting of reduced basal NO activity.
Given the blunted decrease in RPF in response to L-NMMA
in patients with chronic glomerular disease as opposed
to age- and blood pressure-matched control subjects in
our study, patients with chronic glomerular disease appear
to be characterized by a significant reduction in basal
NO activity. Thus, our data in humans support the
concept that chronic glomerular disease is closely linked to
reduced basal NO activity in the renal vascular bed. In
experimental studies, impaired NO activity has been
demonstrated to substantially contribute to the severity of
chronic renal disease.4–11 In these animal models, total and
renal NOS activity is reduced owing to increased circulating
endogenous NOS inhibitors and decreased renal NOS
abundance. Whether similar mechanisms may be involved
in human glomerular disease has not yet been adequately
addressed.
In a series of previous investigations, we have thoroughly
studied the effects of a variety of infusion protocols and doses
of L-NMMA, L-arginine, and vitamin C on RPF in humans.
Although systemic administration of L-NMMA has been
proven to be safe in healthy subjects, potential hazardous
effects of L-NMMA on renal hemodynamics need to be taken
into account if patients with impaired renal function are
studied. For safety reasons, infusion of L-arginine at a dose of
100 mg/kg following L-NMMA infusion has been implemented
in our routine infusion protocol, as previous studies from our
laboratory demonstrated that a dose of 100 mg/kg of L-arginine
can reverse the effects of L-NMMA on renal hemodynamics.13
Accordingly, in this study, RPF returned to baseline levels
after L-arginine infusion. Given the difference in the response
to L-NMMA between our two study groups, the effects
of L-arginine infusion itself are indeed difficult to interpret.
Of note, the change in RPF in response to L-arginine was
not different between the two groups, as was RPF after
L-arginine infusion (5197174 vs 5047122 ml/min/1.73 m2;
P¼NS).
Nevertheless, co-infusion of vitamin C during continuous
administration of L-arginine resulted in an exaggerated
increase in RPF in patients with chronic glomerular disease,
indicative of increased oxidative stress in the renal vascu-
lature of these patients compared to control subjects.
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Figure 2 | Changes of GFR following infusion of L-NMMA,
L-arginine alone, and L-arginine infused concomitantly with the
antioxidant vitamin C. Values are given in mean change from
baseline (%)7s.e.m.
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This notion is clearly supported by studies in the forearm
vasculature, which have demonstrated that in patients with
essential hypertension, non-insulin-dependent diabetes
mellitus or hypercholesterolemia, acetylcholine-induced
endothelium-dependent vasodilation significantly improves
during concomitant infusion of the antioxidant vitamin
C.19–21 These findings clearly support the hypothesis that NO
inactivation by oxygen-derived free radicals contributes to
abnormal vascular reactivity in essential hypertension,
diabetes, and hypercholesterolemia. In accordance with the
findings in the forearm vasculature, systemic administration
of vitamin C during concomitant L-arginine infusion has
repeatedly been demonstrated to be associated with an
augmented increase in RPF in patients prone to increased
oxidative stress, such as smokers16 and type 2 diabetic
patients,15 when compared to healthy control subjects. Thus,
an exaggerated response of RPF to systemic infusion of
vitamin C appears to be indicative of increased oxidative
stress, also in the renal vasculature.
There is indeed convincing evidence to suggest that ROS
play a major role in chronic glomerular disease associated
with impaired endothelial function. In a rat model of
puromycin aminonucleoside glomerulonephritis, levels
of ROS were substantially increased whereas activities of
glomerular antioxidant enzymes were decreased.5 In the same
glomerulonephritis model, increased levels of glomerular
ROS, predominantly H2O2, were measured 2 h after induc-
tion of glomerulonephritis, reaching a peak after 24 h. In
parallel, glomerular concentrations of superoxide dismutase,
catalase, and glutathione peroxidase have been found to be
reduced.22 Similar results were also obtained in other models
of experimental glomerulonephritis.8,9
These animal models provide potential explanations why
patients with chronic kidney disease might be prone to
increased oxidative stress, with chronic inflammation
being an important candidate. Shlipak et al.10 were able to
demonstrate that patients with chronic kidney disease (serum
creatinine levels 41.5 mg/dl in men and 1.3 mg/dl in
women) had elevated levels of acute-phase proteins such as
C-reactive protein, fibrinogen, and interleukin-6, suggesting
that even mild renal failure is associated with inflammation
and vascular injury. Although initially the main source of
ROS in an inflammatory process has been considered to
originate from the leukocyte-derived nicotinamide adenine
dinucleotide phosphate (reduced form) oxidase Nox2, recent
investigations have revealed an expression of Nox2 and its
homologs Nox1, Nox3, Nox4, and Nox5 in non-phagocytotic
cells like the endothelium and mesangium cells of the
kidney.23,24 In addition to serving as a redox-based signaling
molecule, superoxide produced from Nox isoenzymes can
rapidly scavange NO and thereby interfere with its vaso-
dilator effects.25 The relevance of these findings in patients
with chronic glomerular disease remains to be determined.
A possible limitation of our study is the spread of values of
GFR, particularly in our patient group, ranging from 60 to
146 ml/min/1.73 m2. As the error produced by determining
GFR with the constant input clearance technique is reflected
by the duration of insulin administration and the time
taken for plasma insulin values to reach equilibrium levels
and therefore by the reduction in GFR, there may be an
increase in error proportional to the decrease in renal
function. We would also like to point out that our results,
particularly those addressing the abundance of ROS, are
of a more indirect nature and that our interpretation of
the data, although likely, does not necessarily provide a
definite answer.
In conclusion, patients with chronic glomerular disease
display a blunted response of RPF to inhibition of NOS by
L-NMMA and an exaggerated response of RPF to infusion of
the antioxidant vitamin C. Thus, our data support experi-
mental evidence to suggest that basal NO activity is impaired
in patients with chronic glomerular disease, which at least in
part appears to be related to increased oxidative stress.
MATERIALS AND METHODS
Study participants
The study population consisted of 25 patients with chronic
glomerular disease and 50 control subjects recruited from our
outpatient clinics. Patients and controls were either normotensive or
had controlled arterial hypertension defined as casual blood pressure
o140 mmHg systolic and o90 mmHg diastolic, according to
World Health Organization criteria. Major exclusion criteria were
estimated creatinine clearanceo30 ml/min (Cockcroft–Gault), end-
stage renal disease, overt coronary heart disease, congestive heart
failure, hypercholesterolemia (low-density lipoprotein cholesterol
4160 mg/dl), or current lipid-lowering therapy. All participants
were subjected to a thorough medical work-up before inclusion
into the study. Before enrollment, written informed consent was
obtained from each participant. The study was approved by the
Clinical Investigations Ethics Committee of the Friedrich-Alexander
University Erlangen-Nu¨rnberg, Germany.
Study design and assessment of renal hemodynamics
Renal hemodynamic parameters were determined by constant
infusion input clearance technique with insulin (Inutest; Fresenius,
Linz, Austria) and sodium p-aminohippurate (Nephrotest;
Merck, Sharp & Dohme, Hertfordshire, UK) for the measurement
of GFR and RPF, respectively. These procedures have previously
been described in detail.26,27 Renal blood flow is calculated by
dividing RPF by 1-hematocrit, filtration fraction by dividing GFR
by RPF, and renal vascular resistance by dividing mean arterial
blood pressure by renal blood flow.
All subjects fasted overnight for at least 12 h; the examination
itself was performed in a quiet and temperature-controlled
(23–251C) laboratory from 0800 to 1200 hours, with the subject
resting in the supine position. After bolus infusion of insulin and
sodium p-aminohippurate over 15 min and a subsequent constant
infusion over 105 min, a steady state between input and renal
excretion of the tracer substances was reached after 2 h12,13,15 and
the administration of experimental substances was started.
Infusion protocol
L-NMMA was administered intravenously as a bolus infusion
(3 mg/kg over 5 min) followed by constant infusion (1.25 mg/kg
over 25 min). Thus, the total dose of L-NMMA was 4.25 mg/kg.
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Then, L-arginine (L-arginine hydrochloride 6%; University Hospital
Pharmacy, Erlangen, Germany) was administered intravenously at
a dose of 100 mg/kg over 30 min. Over the following 30 min,
L-arginine infusion was continued at 100 mg/kg over 30 min,
but vitamin C (3 g; Cebion-forte; Merck, Darmstadt, Germany)
was co-infused over the same time. Blood samples to determine
insulin and p-aminohippurate concentration were drawn at 0, 120,
150, 180, and 210 min, as described previously in detail.12–17
Throughout the infusion period, blood pressure and heart rate
were monitored every 5 min using an oscillometric device (Dinamap
1846 SX, Critikon, Norderstedt, Germany). The time interval was
changed to one measurement per minute over 5 min before the
collection of blood samples, and mean values were computed from
the five consecutive measurements.
Laboratory measurements
Measurement of p-aminohippurate and insulin was made after
completion of the study from blood samples centrifuged imme-
diately at 41C and stored at 211C. p-Aminohippurate was
measured using the method of Smith et al.;27 insulin was determined
indirectly with an enzymatic method following conversion to fructose.
The actual concentration was then estimated enzymatically (Boehrin-
ger Mannheim, Mannheim, Germany). Each blood sample was
measured in duplicate with a coefficient of variation of o5%.26,28
Statistical analysis
Statistical analyses were performed using the SPSS software package
(SPSS for Windows V13.0, SPSS Inc., Chicago, IL, USA). The
percent change in renal hemodynamic parameters from baseline
was calculated for each variable. A two-way analysis of variance with
a fixed factor corresponding to the groups (patients vs controls) and
a repeated-measures factor for experimental design was performed
to analyze the group differences in both the level and the changes
of renal hemodynamics in response to L-NMMA, L-arginine, and
L-arginine plus vitamin C infusion. Results are given as means7s.d.
in the text and as mean7s.e.m. in the figures. P-values of o0.05
(two-sided) were considered to be significant.
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